Patents by Inventor George Ehrlich

George Ehrlich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glucose-dependent insulinotropic peptide analogs
    Patent number: 9023986
    Abstract: The present invention provides compounds which are analogs of glucose-dependent insulinotropic polypeptide (GIP) and pharmaceutically acceptable salts of such compounds. These compounds have activity as agonists of GIP receptor.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: May 5, 2015
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Waleed Danho, George Ehrlich, Wajiha Khan, Joseph Swistok, Jefferson Wright Tilley
  • Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
    Patent number: 8268784
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. X is 4-oxo-6-(1-piperazinyl)-3(4H)-quinazoline-acetic acid (Pqa). These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: September 18, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Karin Conde-Knape, Waleed Danho, George Ehrlich, Nader Fotouhi, David Charles Fry, Wajiha Khan, Anish Konkar, Cristina Martha Rondinone, Joseph Swistok, Rebecca Anne Taub, Jefferson Wright Tilley
  • GLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE ANALOGS
    Publication number: 20120101037
    Abstract: The present invention provides compounds which are analogs of glucose-dependent insulinotropic polypeptide (GIP) and pharmaceutically acceptable salts of such compounds. These compounds have activity as agonists of GIP receptor.
    Type: Application
    Filed: October 17, 2011
    Publication date: April 26, 2012
    Inventors: Waleed Danho, George Ehrlich, Wajiha Khan, Joseph Swistok, Jefferson Wright Tilley
  • NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF
    Publication number: 20100137223
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. X is 4-oxo-6-(1-piperazinyl)-3(4H)-quinazoline-acetic acid (Pqa). These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
    Type: Application
    Filed: August 6, 2009
    Publication date: June 3, 2010
    Inventors: Karin Conde-Knape, Waleed Danho, George Ehrlich, Nader Fotouhi, David Charles Fry, Wajiha Khan, Anish Konkar, Cristina Martha Rondinone, Joseph Swistok, Rebecca Anne Taub, Jefferson Wright Tilley
  • Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
    Patent number: 7642244
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. X is 4-oxo-6-(1-piperazinyl)-3(4H)-quinazoline-acetic acid (Pqa). These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: January 5, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Karin Conde-Knape, Waleed Danho, George Ehrlich, Nader Fotouhi, David Charles Fry, Wajiha Khan, Anish Konkar, Cristina Martha Rondinone, Joseph Swistok, Rebecca Anne Taub, Jefferson Wright Tilley
  • Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
    Patent number: 7410949
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): Y—R1—R2—X—R3—R4—R5—R6—R7—R8—R9—R10—R11—R12—R13—R14—NH2, ??(I) as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: August 12, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Waleed Danho, George Ehrlich, David C Fry, Wajiha Khan, Joseph Swistok
  • Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
    Publication number: 20070135351
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
    Type: Application
    Filed: December 1, 2006
    Publication date: June 14, 2007
    Inventors: Karin Conde-Knape, Waleed Danho, George Ehrlich, Nader Fotouhi, David Fry, Wajiha Khan, Anish Konkar, Cristina Rondinone, Joseph Swistok, Rebecca Taub, Jefferson Tilley
  • Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
    Publication number: 20060160742
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): Y—R1—R2—X—R3—R4—R5—R6—R7—R8—R9—R10—R11—R12—R13—R14—NH2??(I), as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.
    Type: Application
    Filed: January 10, 2006
    Publication date: July 20, 2006
    Inventors: Waleed Danho, George Ehrlich, David Fry, Wajiha Khan, Joseph Swistok